Table 1.

Baseline characteristics of patients.

	All (N = 12)	DL1 (N = 3)	DL2 (N = 3)	DL3 (N = 3)	DL4 (N = 3)
Age, years	65 (45–74)	60 (55–74)	58 (52–65)	50 (45–67)	66 (65–67)
Sex
Female	6 (50%)	1 (33%)	3 (100%)	2 (67%)	0 (0%)
Male	6 (50%)	2 (67%)	0 (0%)	1 (33%)	3 (100%)
Time from diagnosis, months	13 (6–96)	13 (11–21)	8 (7–12)	28 (21–35)	6 (6–96)
Disease—No. (%)
DLBCL	11 (92)	3 (100%)	2 (67%)	3 (100%)	3 (100%)
HGBL	1 (8%)	0 (0%)	1 (33%)	0 (0%)	0 (0%)
Disease Stage—No. (%)
Ⅱ	2 (17%)	0 (0%)	0 (0%)	2 (67%)	0 (0%)
Ⅲ	2 (17%)	1 (33%)	1 (33%)	0 (0%)	0 (0%)
Ⅳ	8 (66%)	2 (67%)	2 (67%)	1 (33%)	3 (100%)
≥3 IPI score—No. (%)	9 (75%)	2 (67%)	2 (67%)	2 (67%)	3 (100%)
Blood LDH increased—No. (%)	9 (75%)	2 (67%)	2 (67%)	2 (67%)	3 (100%)
Prior therapies—No. (%)
≥3 prior lines of therapy	9 (75%)	3 (100%)	2 (67%)	2 (67%)	2 (67%)
BTK inhibitors ± combinations	5 (42%)	2 (67%)	1 (33%)	0 (0%)	2 (67%)
Lenalidomide	4 (33%)	2 (67%)	0 (0%)	2 (67%)	0 (0%)
Venetoclax	1 (8%)	1 (33%)	0 (0%)	0 (0%)	0 (0%)
Refractory status at study entry
Complete response	5 (42%)	2 (67%)	0 (0%)	2 (67%)	1 (33%)
Partial response	4 (33%)	1 (33%)	1 (33%)	1 (33%)	1 (33%)
Stable disease	2 (17%)	0 (0%)	1 (33%)	0 (0%)	1 (33%)
Progressive disease	1 (8%)	0 (0%)	1 (33%)	0 (0%)	0 (0%)

Note: Data are median (IQR) or No (%), DL, Dose Level.